The growing menace of antibiotic resistance is, arguably, the single biggest threat faced by the world's population. However, in 2014 a change in direction has occurred with the announcement of two new antibiotics.
The first of the new antibiotics is called Dalvance. This is an intravenous drug that can treat skin and soft tissue infections.
The second drug is called Oritavancin. Oritavancin is a lipoglycopeptide with bactericidal activity against Gram-positive bacteria.
Both of these new antibiotics are discussed in a new paper by Tim Sandle.